Published in Nat Rev Immunol on August 01, 2004
Cellular and molecular mechanisms of fibrosis. J Pathol (2008) 14.01
Protective and pathogenic functions of macrophage subsets. Nat Rev Immunol (2011) 12.21
Common and unique mechanisms regulate fibrosis in various fibroproliferative diseases. J Clin Invest (2007) 6.56
Mechanisms of fibrosis: therapeutic translation for fibrotic disease. Nat Med (2012) 6.15
Protective immune mechanisms in helminth infection. Nat Rev Immunol (2007) 5.66
Systemic sclerosis: a prototypic multisystem fibrotic disorder. J Clin Invest (2007) 5.19
Distinct macrophage phenotypes contribute to kidney injury and repair. J Am Soc Nephrol (2011) 4.76
Toll-like receptor-induced arginase 1 in macrophages thwarts effective immunity against intracellular pathogens. Nat Immunol (2008) 4.31
Macrophages: master regulators of inflammation and fibrosis. Semin Liver Dis (2010) 4.24
Memory T(H)2 cells induce alternatively activated macrophages to mediate protection against nematode parasites. Nat Med (2006) 4.16
Arginase-1-expressing macrophages suppress Th2 cytokine-driven inflammation and fibrosis. PLoS Pathog (2009) 4.12
Epigenetic regulation of the alternatively activated macrophage phenotype. Blood (2009) 3.76
Intratumor T helper type 2 cell infiltrate correlates with cancer-associated fibroblast thymic stromal lymphopoietin production and reduced survival in pancreatic cancer. J Exp Med (2011) 3.59
Integrating mechanisms of pulmonary fibrosis. J Exp Med (2011) 3.57
Cross-regulation of signaling pathways by interferon-gamma: implications for immune responses and autoimmune diseases. Immunity (2009) 3.51
The IL-21 receptor augments Th2 effector function and alternative macrophage activation. J Clin Invest (2006) 3.33
Reversal of persistent fibrosis in aging by targeting Nox4-Nrf2 redox imbalance. Sci Transl Med (2014) 3.23
Pulmonary fibrosis: pathogenesis, etiology and regulation. Mucosal Immunol (2009) 3.13
Phenotypic and functional plasticity of cells of innate immunity: macrophages, mast cells and neutrophils. Nat Immunol (2011) 2.92
The IL-33/ST2 pathway: therapeutic target and novel biomarker. Nat Rev Drug Discov (2008) 2.90
Microglia and brain macrophages in the molecular age: from origin to neuropsychiatric disease. Nat Rev Neurosci (2014) 2.59
Renal fibrosis: novel insights into mechanisms and therapeutic targets. Nat Rev Nephrol (2010) 2.55
Hypertrophic scarring and keloids: pathomechanisms and current and emerging treatment strategies. Mol Med (2010) 2.51
Alternatively activated macrophage-derived RELM-{alpha} is a negative regulator of type 2 inflammation in the lung. J Exp Med (2009) 2.51
Unique functions of the type II interleukin 4 receptor identified in mice lacking the interleukin 13 receptor alpha1 chain. Nat Immunol (2007) 2.50
Interactions between lymphocytes and myeloid cells regulate pro- versus anti-tumor immunity. Cancer Metastasis Rev (2010) 2.41
Aberrant repair and fibrosis development in skeletal muscle. Skelet Muscle (2011) 2.41
Morphometric and visual evaluation of fibrosis in renal biopsies. J Am Soc Nephrol (2010) 2.32
Pivotal Advance: Th-1 cytokines inhibit, and Th-2 cytokines promote fibrocyte differentiation. J Leukoc Biol (2008) 2.30
Liver fibrosis and repair: immune regulation of wound healing in a solid organ. Nat Rev Immunol (2014) 2.29
Evolution of Th2 immunity: a rapid repair response to tissue destructive pathogens. PLoS Pathog (2011) 2.25
Adipose tissue transcriptomic signature highlights the pathological relevance of extracellular matrix in human obesity. Genome Biol (2008) 2.22
TGF-β in progression of liver disease. Cell Tissue Res (2011) 2.22
Host responses in tissue repair and fibrosis. Annu Rev Pathol (2012) 2.10
Retnla (relmalpha/fizz1) suppresses helminth-induced Th2-type immunity. PLoS Pathog (2009) 2.07
Novel effector molecules in type 2 inflammation: lessons drawn from helminth infection and allergy. J Immunol (2006) 1.94
Fibrocytes represent a novel MDSC subset circulating in patients with metastatic cancer. Blood (2013) 1.85
Coinfection with HIV-1 and HCV--a one-two punch. Gastroenterology (2009) 1.78
Patients with idiopathic pulmonary fibrosis with antibodies to heat shock protein 70 have poor prognoses. Am J Respir Crit Care Med (2013) 1.77
Interleukin-5 (IL-5) augments the progression of liver fibrosis by regulating IL-13 activity. Infect Immun (2006) 1.76
Activation of alveolar macrophages via the alternative pathway in herpesvirus-induced lung fibrosis. Am J Respir Cell Mol Biol (2006) 1.75
Fibrinogen drives dystrophic muscle fibrosis via a TGFbeta/alternative macrophage activation pathway. Genes Dev (2008) 1.73
Dendritic cells are specialized accessory cells along with TGF- for the differentiation of Foxp3+ CD4+ regulatory T cells from peripheral Foxp3 precursors. Blood (2007) 1.70
Class I HDACs regulate angiotensin II-dependent cardiac fibrosis via fibroblasts and circulating fibrocytes. J Mol Cell Cardiol (2013) 1.70
IgG4-related autoimmune diseases: Polymorphous presentation complicates diagnosis and treatment. Dtsch Arztebl Int (2015) 1.70
Thymic stromal lymphopoietin amplifies the differentiation of alternatively activated macrophages. J Immunol (2012) 1.69
Infectious disease, the innate immune response, and fibrosis. J Clin Invest (2007) 1.68
Semaphorin 7A plays a critical role in TGF-beta1-induced pulmonary fibrosis. J Exp Med (2007) 1.67
Arginine usage in mycobacteria-infected macrophages depends on autocrine-paracrine cytokine signaling. Sci Signal (2010) 1.66
B-lymphocyte depletion reduces skin fibrosis and autoimmunity in the tight-skin mouse model for systemic sclerosis. Am J Pathol (2006) 1.64
Type 2 cytokines: mechanisms and therapeutic strategies. Nat Rev Immunol (2015) 1.57
Future directions in idiopathic pulmonary fibrosis research. An NHLBI workshop report. Am J Respir Crit Care Med (2014) 1.54
Analysis of the transcriptional networks underpinning the activation of murine macrophages by inflammatory mediators. J Leukoc Biol (2014) 1.53
mTOR inhibition rescues osteopenia in mice with systemic sclerosis. J Exp Med (2014) 1.52
JAK3/STAT6 Stimulates Bone Marrow-Derived Fibroblast Activation in Renal Fibrosis. J Am Soc Nephrol (2015) 1.51
Periostin promotes chronic allergic inflammation in response to Th2 cytokines. J Clin Invest (2012) 1.51
Review series on helminths, immune modulation and the hygiene hypothesis: mechanisms underlying helminth modulation of dendritic cell function. Immunology (2009) 1.48
Renal interstitial fibrosis: mechanisms and evaluation. Curr Opin Nephrol Hypertens (2012) 1.46
Macrophage plasticity and the role of inflammation in skeletal muscle repair. Mediators Inflamm (2013) 1.40
Transcription factor T-bet regulates skin sclerosis through its function in innate immunity and via IL-13. Proc Natl Acad Sci U S A (2007) 1.39
Molecular and cellular mechanisms of pulmonary fibrosis. Fibrogenesis Tissue Repair (2012) 1.37
Interleukin-33 overexpression is associated with liver fibrosis in mice and humans. J Cell Mol Med (2009) 1.36
Gene discovery for the carcinogenic human liver fluke, Opisthorchis viverrini. BMC Genomics (2007) 1.35
Differential polarization of alveolar macrophages and bone marrow-derived monocytes following chemically and pathogen-induced chronic lung inflammation. J Leukoc Biol (2010) 1.35
Matrix metalloproteinase 12-deficiency augments extracellular matrix degrading metalloproteinases and attenuates IL-13-dependent fibrosis. J Immunol (2010) 1.35
IL-31-IL-31R interactions negatively regulate type 2 inflammation in the lung. J Exp Med (2007) 1.34
Murine models of chronic graft-versus-host disease: insights and unresolved issues. Biol Blood Marrow Transplant (2008) 1.32
Interspecies comparison of human and murine scleroderma reveals IL-13 and CCL2 as disease subset-specific targets. Am J Pathol (2012) 1.32
Fibrotic myofibroblasts manifest genome-wide derangements of translational control. PLoS One (2008) 1.30
Targeting fibrosis in Duchenne muscular dystrophy. J Neuropathol Exp Neurol (2010) 1.27
c-Jun N-terminal kinase 1 is required for the development of pulmonary fibrosis. Am J Respir Cell Mol Biol (2008) 1.26
Restoration of tumor immunosurveillance via targeting of interleukin-13 receptor-alpha 2. Cancer Res (2008) 1.26
Interleukin-6 signaling drives fibrosis in unresolved inflammation. Immunity (2014) 1.25
Elevated epithelial expression of interleukin-8 correlates with myofibroblast reactive stroma in benign prostatic hyperplasia. Urology (2008) 1.24
Novel therapeutic approaches for pulmonary fibrosis. Br J Pharmacol (2011) 1.24
Inflammation and Spinal Cord Injury: Infiltrating Leukocytes as Determinants of Injury and Repair Processes. Clin Neurosci Res (2006) 1.24
A novel mechanism for CCR4 in the regulation of macrophage activation in bleomycin-induced pulmonary fibrosis. Am J Pathol (2008) 1.24
Molecular mechanism of hepatic stellate cell activation and antifibrotic therapeutic strategies. J Gastroenterol (2008) 1.23
Macrophages in Tissue Repair, Regeneration, and Fibrosis. Immunity (2016) 1.22
Adenosine metabolism and murine strain-specific IL-4-induced inflammation, emphysema, and fibrosis. J Clin Invest (2006) 1.22
Dynamic mast cell-stromal cell interactions promote growth of pancreatic cancer. Cancer Res (2013) 1.21
Trachoma: protective and pathogenic ocular immune responses to Chlamydia trachomatis. PLoS Negl Trop Dis (2013) 1.20
Cationic amino acid transporter-2 regulates immunity by modulating arginase activity. PLoS Pathog (2008) 1.19
Mina, an Il4 repressor, controls T helper type 2 bias. Nat Immunol (2009) 1.18
Insulin-like growth factor-binding protein-5 induces pulmonary fibrosis and triggers mononuclear cellular infiltration. Am J Pathol (2006) 1.17
Radiation-induced heart disease: pathologic abnormalities and putative mechanisms. Front Oncol (2015) 1.17
Conjunctival expression of matrix metalloproteinase and proinflammatory cytokine genes after trichiasis surgery. Invest Ophthalmol Vis Sci (2010) 1.16
Similarity and diversity in macrophage activation by nematodes, trematodes, and cestodes. J Biomed Biotechnol (2010) 1.16
Mouse models of graft-versus-host disease: advances and limitations. Dis Model Mech (2011) 1.16
Molecular control of physiological and pathological T-cell recruitment after mouse spinal cord injury. J Neurosci (2005) 1.16
Graft versus host disease in the bone marrow, liver and thymus humanized mouse model. PLoS One (2012) 1.16
Diverse functions of matrix metalloproteinases during fibrosis. Dis Model Mech (2014) 1.16
The immunomodulatory properties of mesenchymal stem cells. Semin Immunopathol (2011) 1.16
Mononuclear cells in liver fibrosis. Semin Immunopathol (2009) 1.15
Conjunctival transcriptome in scarring trachoma. Infect Immun (2010) 1.15
Fibrosis: ultimate and proximate causes. J Clin Invest (2014) 1.15
Pathological functions of interleukin-22 in chronic liver inflammation and fibrosis with hepatitis B virus infection by promoting T helper 17 cell recruitment. Hepatology (2014) 1.14
The biology of thymic stromal lymphopoietin (TSLP). Adv Pharmacol (2013) 1.12
Characterisation of effector mechanisms at the host:parasite interface during the immune response to tissue-dwelling intestinal nematode parasites. Int J Parasitol (2008) 1.11
Emerging role of the interleukin (IL)-33/ST2 axis in gut mucosal wound healing and fibrosis. Fibrogenesis Tissue Repair (2012) 1.11
Alternative activation of macrophages. Nat Rev Immunol (2003) 27.53
Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol (2001) 25.63
Functional diversity of helper T lymphocytes. Nature (1996) 18.09
Interleukin-13: central mediator of allergic asthma. Science (1998) 14.05
The integrin alpha v beta 6 binds and activates latent TGF beta 1: a mechanism for regulating pulmonary inflammation and fibrosis. Cell (1999) 11.59
Transforming growth factor beta 1 null mutation in mice causes excessive inflammatory response and early death. Proc Natl Acad Sci U S A (1993) 10.82
Requirement for IL-13 independently of IL-4 in experimental asthma. Science (1998) 10.76
Pulmonary expression of interleukin-13 causes inflammation, mucus hypersecretion, subepithelial fibrosis, physiologic abnormalities, and eotaxin production. J Clin Invest (1999) 8.38
Regulation of immune responses by TGF-beta. Annu Rev Immunol (1998) 8.01
Viral hepatitis C. Lancet (2003) 5.81
Adenovector-mediated gene transfer of active transforming growth factor-beta1 induces prolonged severe fibrosis in rat lung. J Clin Invest (1997) 5.77
Mice lacking Smad3 show accelerated wound healing and an impaired local inflammatory response. Nat Cell Biol (1999) 5.58
Interleukin-13 induces tissue fibrosis by selectively stimulating and activating transforming growth factor beta(1). J Exp Med (2001) 4.71
Differential regulation of nitric oxide synthase-2 and arginase-1 by type 1/type 2 cytokines in vivo: granulomatous pathology is shaped by the pattern of L-arginine metabolism. J Immunol (2001) 4.59
Targeted disruption of TGF-beta1/Smad3 signaling protects against renal tubulointerstitial fibrosis induced by unilateral ureteral obstruction. J Clin Invest (2003) 4.58
Transforming growth factor-beta in T-cell biology. Nat Rev Immunol (2002) 4.50
An IL-13 inhibitor blocks the development of hepatic fibrosis during a T-helper type 2-dominated inflammatory response. J Clin Invest (1999) 4.22
Dissection of experimental asthma with DNA microarray analysis identifies arginase in asthma pathogenesis. J Clin Invest (2003) 4.08
Alternative metabolic states in murine macrophages reflected by the nitric oxide synthase/arginase balance: competitive regulation by CD4+ T cells correlates with Th1/Th2 phenotype. J Immunol (1998) 3.98
Natural inhibitor of transforming growth factor-beta protects against scarring in experimental kidney disease. Nature (1992) 3.96
Th1/Th2-regulated expression of arginase isoforms in murine macrophages and dendritic cells. J Immunol (1999) 3.68
The enemy within: keeping self-reactive T cells at bay in the periphery. Nat Rev Immunol (2002) 3.47
Global analysis of gene expression in pulmonary fibrosis reveals distinct programs regulating lung inflammation and fibrosis. Proc Natl Acad Sci U S A (2000) 3.47
Allergen-specific Th1 cells fail to counterbalance Th2 cell-induced airway hyperreactivity but cause severe airway inflammation. J Clin Invest (1999) 3.32
Inhibition of airway remodeling in IL-5-deficient mice. J Clin Invest (2004) 3.06
IL-10 and the dangers of immune polarization: excessive type 1 and type 2 cytokine responses induce distinct forms of lethal immunopathology in murine schistosomiasis. J Immunol (2000) 3.03
Schistosome infection of transgenic mice defines distinct and contrasting pathogenic roles for IL-4 and IL-13: IL-13 is a profibrotic agent. J Immunol (2000) 2.89
Interleukin 10 treatment reduces fibrosis in patients with chronic hepatitis C: a pilot trial of interferon nonresponders. Gastroenterology (2000) 2.83
Impaired host defense, hematopoiesis, granulomatous inflammation and type 1-type 2 cytokine balance in mice lacking CC chemokine receptor 1. J Exp Med (1997) 2.79
Regulation and function of the interleukin 13 receptor alpha 2 during a T helper cell type 2-dominant immune response. J Exp Med (2003) 2.71
Phenotypic and physiologic characterization of transgenic mice expressing interleukin 4 in the lung: lymphocytic and eosinophilic inflammation without airway hyperreactivity. Proc Natl Acad Sci U S A (1996) 2.70
Impaired development of Th2 cells in IL-13-deficient mice. Immunity (1998) 2.68
Critical role for IL-13 in the development of allergen-induced airway hyperreactivity. J Immunol (2001) 2.63
The murine IL-13 receptor alpha 2: molecular cloning, characterization, and comparison with murine IL-13 receptor alpha 1. J Immunol (1998) 2.57
Enhanced interleukin (IL)-13 responses in mice lacking IL-13 receptor alpha 2. J Exp Med (2003) 2.54
Overlapping and enzyme-specific contributions of matrix metalloproteinases-9 and -12 in IL-13-induced inflammation and remodeling. J Clin Invest (2002) 2.52
An IL-12-based vaccination method for preventing fibrosis induced by schistosome infection. Nature (1995) 2.52
The pathogenesis of schistosomiasis is controlled by cooperating IL-10-producing innate effector and regulatory T cells. J Immunol (2004) 2.50
Global gene expression profiles during acute pathogen-induced pulmonary inflammation reveal divergent roles for Th1 and Th2 responses in tissue repair. J Immunol (2003) 2.48
IL-13 activates a mechanism of tissue fibrosis that is completely TGF-beta independent. J Immunol (2004) 2.47
Critical role for the chemokine MCP-1/CCR2 in the pathogenesis of bronchiolitis obliterans syndrome. J Clin Invest (2001) 2.39
Protection from pulmonary fibrosis in the absence of CCR2 signaling. J Immunol (2001) 2.38
Interleukin 5 is required for the blood and tissue eosinophilia but not granuloma formation induced by infection with Schistosoma mansoni. Proc Natl Acad Sci U S A (1990) 2.37
Anti-IL-4 treatment of Schistosoma mansoni-infected mice inhibits development of T cells and non-B, non-T cells expressing Th2 cytokines while decreasing egg-induced hepatic fibrosis. J Immunol (1994) 2.25
Mice lacking Smad3 are protected against cutaneous injury induced by ionizing radiation. Am J Pathol (2002) 2.23
Interleukin-10 expression and function in experimental murine liver inflammation and fibrosis. Hepatology (1998) 2.19
Receptors for interleukin-13 and interleukin-4 are complex and share a novel component that functions in signal transduction. EMBO J (1993) 2.18
Transforming growth factor-beta-dependent and -independent pathways of induction of tubulointerstitial fibrosis in beta6(-/-) mice. Am J Pathol (2003) 2.05
Intrinsic defect in T cell production of interleukin (IL)-13 in the absence of both IL-5 and eotaxin precludes the development of eosinophilia and airways hyperreactivity in experimental asthma. J Exp Med (2002) 2.04
Interleukin-10 controls neutrophilic infiltration, hepatocyte proliferation, and liver fibrosis induced by carbon tetrachloride in mice. Hepatology (1998) 2.04
Cooperation between Th1 and Th2 cells in a murine model of eosinophilic airway inflammation. J Clin Invest (1999) 1.99
Interaction of IL-13 and C10 in the pathogenesis of bleomycin-induced pulmonary fibrosis. Am J Respir Cell Mol Biol (2002) 1.95
Studies of murine schistosomiasis reveal interleukin-13 blockade as a treatment for established and progressive liver fibrosis. Hepatology (2001) 1.90
Interleukin (IL) 4 and IL-13 act on human lung fibroblasts. Implication in asthma. J Clin Invest (1998) 1.84
IL-13-induced chemokine responses in the lung: role of CCR2 in the pathogenesis of IL-13-induced inflammation and remodeling. J Immunol (2002) 1.81
IL-13 receptor alpha 2 down-modulates granulomatous inflammation and prolongs host survival in schistosomiasis. Proc Natl Acad Sci U S A (2003) 1.80
Hepatic fibrosis, glomerulosclerosis, and a lipodystrophy-like syndrome in PEPCK-TGF-beta1 transgenic mice. J Clin Invest (1997) 1.79
Molecular mechanisms of antifibrotic effect of interferon gamma in bleomycin-mouse model of lung fibrosis: downregulation of TGF-beta and procollagen I and III gene expression. Exp Lung Res (1996) 1.77
Long-term interleukin 10 therapy in chronic hepatitis C patients has a proviral and anti-inflammatory effect. Hepatology (2003) 1.76
Plasmin regulates the activation of cell-associated latent TGF-beta 1 secreted by rat alveolar macrophages after in vivo bleomycin injury. Am J Respir Cell Mol Biol (1996) 1.75
SB 239063, a p38 MAPK inhibitor, reduces neutrophilia, inflammatory cytokines, MMP-9, and fibrosis in lung. Am J Physiol Lung Cell Mol Physiol (2000) 1.75
Il-13 and IFN-gamma: interactions in lung inflammation. J Immunol (2001) 1.75
Smad3: a key player in pathogenetic mechanisms dependent on TGF-beta. Ann N Y Acad Sci (2003) 1.74
A chemokine receptor CCR-1 antagonist reduces renal fibrosis after unilateral ureter ligation. J Clin Invest (2002) 1.70
NOS-2 mediates the protective anti-inflammatory and antifibrotic effects of the Th1-inducing adjuvant, IL-12, in a Th2 model of granulomatous disease. Am J Pathol (2000) 1.67
A role for C-C chemokines in fibrotic lung disease. J Leukoc Biol (1995) 1.60
Periportal fibrosis in human Schistosoma mansoni infection is associated with low IL-10, low IFN-gamma, high TNF-alpha, or low RANTES, depending on age and gender. J Immunol (2004) 1.57
Regulation of hepatic fibrosis and extracellular matrix genes by the th response: new insight into the role of tissue inhibitors of matrix metalloproteinases. J Immunol (2001) 1.55
Transgenic overexpression of interleukin (IL)-10 in the lung causes mucus metaplasia, tissue inflammation, and airway remodeling via IL-13-dependent and -independent pathways. J Biol Chem (2002) 1.54
IL-10 regulates liver pathology in acute murine Schistosomiasis mansoni but is not required for immune down-modulation of chronic disease. J Immunol (1998) 1.54
Interleukin-13 modulates collagen homeostasis in human skin and keloid fibroblasts. J Pharmacol Exp Ther (2000) 1.54
A type 2 (Th2-like) pattern of immune response predominates in the pulmonary interstitium of patients with cryptogenic fibrosing alveolitis (CFA). Clin Exp Immunol (1995) 1.50
The role of IL-13 in established allergic airway disease. J Immunol (2002) 1.48
Subsets of murine lung fibroblasts express membrane-bound and soluble IL-4 receptors. Role of IL-4 in enhancing fibroblast proliferation and collagen synthesis. J Immunol (1994) 1.46
BMP7 antagonizes TGF-beta -dependent fibrogenesis in mesangial cells. Am J Physiol Renal Physiol (2003) 1.46
Blockade of transforming growth factor beta/Smad signaling in T cells by overexpression of Smad7 enhances antigen-induced airway inflammation and airway reactivity. J Exp Med (2000) 1.45
CD4(+) T helper cells engineered to produce latent TGF-beta1 reverse allergen-induced airway hyperreactivity and inflammation. J Clin Invest (2000) 1.43
Production and function of murine macrophage inflammatory protein-1 alpha in bleomycin-induced lung injury. J Immunol (1994) 1.42
Airway subepithelial fibrosis in a murine model of atopic asthma: suppression by dexamethasone or anti-interleukin-5 antibody. Am J Respir Cell Mol Biol (2000) 1.41
Integrated signals between IL-13, IL-4, and IL-5 regulate airways hyperreactivity. J Immunol (2000) 1.41
IL-13 induces airways hyperreactivity independently of the IL-4R alpha chain in the allergic lung. J Immunol (2001) 1.41
Lysyl oxidase-like protein localizes to sites of de novo fibrinogenesis in fibrosis and in the early stromal reaction of ductal breast carcinomas. Lab Invest (1998) 1.40
The C10/CCL6 chemokine and CCR1 play critical roles in the pathogenesis of IL-13-induced inflammation and remodeling. J Immunol (2004) 1.37
Role of interleukin-13 in eosinophil accumulation and airway remodelling in a mouse model of chronic asthma. Clin Exp Allergy (2002) 1.37
Critical roles for IL-4, IL-5, and eosinophils in chronic skin allograft rejection. J Clin Invest (1999) 1.35
Therapeutic effect of IL-13 immunoneutralization during chronic experimental fungal asthma. J Immunol (2001) 1.35
Proteome analysis of rat hepatic stellate cells. Hepatology (2000) 1.34
Stat6-deficient mice develop airway hyperresponsiveness and peribronchial fibrosis during chronic fungal asthma. Am J Pathol (2002) 1.34
Expression of interleukin-10 by in vitro and in vivo activated hepatic stellate cells. J Biol Chem (1998) 1.33
Interferon-gamma inhibits experimental renal fibrosis. Kidney Int (1999) 1.30
Disease fingerprinting with cDNA microarrays reveals distinct gene expression profiles in lethal type 1 and type 2 cytokine-mediated inflammatory reactions. FASEB J (2001) 1.30
IL-12 attenuates bleomycin-induced pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol (2001) 1.29
Blockade of CD40-CD40 ligand interactions protects against radiation-induced pulmonary inflammation and fibrosis. Clin Immunol Immunopathol (1998) 1.28
Cytokine regulation of IL-13Ralpha2 and IL-13Ralpha1 in vivo and in vitro. J Allergy Clin Immunol (2003) 1.27
Introduction of the interleukin-10 gene into mice inhibited bleomycin-induced lung injury in vivo. Am J Physiol Lung Cell Mol Physiol (2000) 1.23
Local production of interleukin-4 during radiation-induced pneumonitis and pulmonary fibrosis in rats: macrophages as a prominent source of interleukin-4. Am J Respir Cell Mol Biol (1997) 1.22
Eosinophils and T lymphocytes possess distinct roles in bleomycin-induced lung injury and fibrosis. J Immunol (2003) 1.21
Potential action of IL-4 and IL-13 as fibrogenic factors on lung fibroblasts in vitro. Int Arch Allergy Immunol (2003) 1.21